Search

Your search keyword '"Bi, Jingwang"' showing total 47 results
Start Over Author "Bi, Jingwang"
47 results on '"Bi, Jingwang"'

2. Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial

Author

Wei, Zhigang, Yang, Xia, Ye, Xin, Feng, Qingliang, Xu, Yanjun, Zhang, Licheng, Sun, Wenqiao, Dong, Yuting, Meng, Qi, Li, Tao, Wang, Chuntang, Li, Guangxu, Zhang, Kaixian, Li, Peishun, Bi, Jingwang, Xue, Guoliang, Sun, Yahong, Sheng, Lijun, Liu, Bin, Yu, Guohua, Ren, Haipeng, Wang, Junye, Sun, Lijun, Chen, Shaoshui, Geng, Dianzhong, Zhang, Benhua, Xu, Xin, Zhang, Liangming, Sun, Dengjun, Xu, Xinglu, Diao, Cunqi, Huang, Guanghui, Li, Wenhong, Han, Xiaoying, Wang, Jiao, Meng, Min, Ni, Yang, Zheng, Aimin, Fan, Weijun, Li, Yuliang, Li, Fan, Fan, Hua, Zou, Zhigeng, Li, Qingyu, and Tian, Hui

Published
2020
Full Text
View/download PDF

22. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer

Author

Li-li Wang, Qing-hua Ma, Shiwei Zhao, Bi Jingwang, Shi Yanlong, Kai Zhou, Ze-Xuan Yan, Liu Yulin, Qiang Wang, Ting-ting Shi, Li-Li Xu, and Hui-li Chu

Subjects
Adult, Male, 0301 basic medicine, Cancer Research, Cell Survival, Class I Phosphatidylinositol 3-Kinases, Colorectal cancer, Morpholines, Phosphorylcholine, medicine.medical_treatment, Immunology, Article, Receptors, G-Protein-Coupled, 03 medical and health sciences, Cellular and Molecular Neuroscience, 0302 clinical medicine, Humans, Medicine, lcsh:QH573-671, Mutation frequency, neoplasms, PI3K/AKT/mTOR pathway, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, biology, lcsh:Cytology, business.industry, LGR5, Cell Biology, Middle Aged, HCT116 Cells, medicine.disease, digestive system diseases, 030104 developmental biology, Chromones, 030220 oncology & carcinogenesis, Multivariate Analysis, Mutation, Mutation (genetic algorithm), Cancer research, biology.protein, Female, Fluorouracil, Antibody, Stem cell, Colorectal Neoplasms, business
Abstract

Chemotherapy represents an important treatment option for colorectal cancer (CRC), but only half of the patients benefit from these regimens. We explored the potential predicting value and mechanism of PIK3CA mutation in CRC chemotherapy. CRC specimens from 440 patients were retrospectively collected and examined with a fluorescence PCR-based method. The correlation of first-line chemotherapy response and PIK3CA mutation was evaluated according to follow-up and medical records. The underlying mechanism of PIK3CA mutation in chemotherapy resistance was assessed with CRC tumors and primary cells. The mutation frequency of the PIK3CA gene in CRC patients was 9.55%, which was correlated with late TNM staging and lower histological grade. The CRC patients with PIK3A mutation showed worse response to first-line chemotherapy than those without PIK3CA mutation. PIK3A mutation tumor cells showed poor sensitivity to first-line chemotherapy in vitro and in vivo. PIK3CA mutation induced PI3K/Akt signaling activation to increase LGR5+ CRC stem cells survival and proliferation, from which lead to chemotherapy resistance. Furthermore, PIK3CAmutation/LGR5+ expression was an independent detrimental factor for CRC patients. Our findings indicated that PIK3CA mutation induced PI3K/Akt activation contributed to CRC stem cells survival and proliferation, from which cells further resistance to chemotherapy. PIK3CA mutation/LGR5+ expression was a potential biomarker for monitoring chemotherapy resistance in CRC.

Published
2018

25. P2.04-025 Recombinant Human Endostatin and/or Cisplatin in Treatment of Malignant Hydrothorax and Ascites: A Multicenter Randomized Study

Author

Qin, Shukui, primary, Cheng, Ying, additional, Tan, Qinghe, additional, Bi, Jingwang, additional, Wang, Liwei, additional, Hu, Bing, additional, Shi, Jianhua, additional, Sun, Guoping, additional, Bai, Yuxian, additional, Tao, Min, additional, Guo, Weijian, additional, Lu, Bing, additional, Liang, Jun, additional, and Zhang, Helong, additional

Published
2017
Full Text
View/download PDF

26. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment

Author

Ni, Yang, primary, Bi, Jingwang, additional, Ye, Xin, additional, Fan, Weijun, additional, Yu, Guohua, additional, Yang, Xia, additional, Huang, Guanghui, additional, Li, Wenhong, additional, Wang, Jiao, additional, Han, Xiaoying, additional, Ni, Xiang, additional, Wei, Zhigang, additional, Han, Mingyong, additional, Zheng, Aimin, additional, Meng, Min, additional, Xue, Guoliang, additional, Zhang, Liang, additional, and Wan, Chao, additional

Published
2016
Full Text
View/download PDF

29. A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of famitinib in the treatment of advanced metastatic colorectal cancer.

Author

Xu, Rui-hua, primary, Shen, Lin, additional, Wang, Keming, additional, Wu, Gang, additional, Shi, Chunmei, additional, Ding, Kefeng, additional, Lin, Lizhu, additional, Wang, Jinwan, additional, Xiong, Jianping, additional, Wu, Changping, additional, Li, Jin, additional, Liu, Yunpeng, additional, Wang, Dong, additional, Ba, Yi, additional, Feng, Jueping, additional, Bai, Yuxian, additional, Bi, JingWang, additional, MA, Liwen, additional, Lei, Jian, additional, and Yu, Hao, additional

Published
2015
Full Text
View/download PDF

45. Prognostic significance of microvascular invasion and microlymphatic permeation in non-small-cell lung cancer.

Author

Wang, Jun, Wang, Baocheng, Bi, Jingwang, and Li, Kainan

Subjects
LETTERS to the editor, LUNG cancer, PROGNOSTIC tests
Abstract

A letter to the editor is presented in response to the article "Prognostic impact of intratumoural invasion and microlymphatic permeation on node-negative non-small-cell lung cancer: which indicator is the stronger prognostic factor?," by T. Hishida et al, published in a previous issue.

Published
2013
Full Text
View/download PDF

46. Association Study of Single Nucleotide Polymorphisms in XRCC1 Gene with Risk of Hepatocellular Carcinoma in Chinese Han Population.

Author

Bi, Jingwang, Zhong, Chen, Li, Kainan, Chu, Huili, and Wang, Baocheng

Abstract

Hepatocellular carcinoma (HCC) is one of the most frequently causing cancer-related deaths worldwide. Previous evidence suggests that the X-ray repair cross-complementing group 1 gene (XRCC1) is an important candidate gene for influencing the risk of HCC. The aim of this study was to assess the association of XRCC1 genetic polymorphisms with the risk of HCC in Chinese Han population. A total of 1314 subjects, including 651 HCC patients and 663 healthy controls, were enrolled in this case-control study. Two genetic variants (c.1254C>T and c.1517G>C) in XRCC1 gene were genotyped by created restriction site-polymerase chain reaction (CRS-PCR) and PCR-restriction fragment length polymorphism (PCR-RFLP) methods. Our data indicated that the allele and genotype frequencies of these two genetic variants were statistical difference in HCC cases and healthy controls. Association analyses suggested that these two genetic variants were statistically associated with the increased risk of HCC in all genetic models (for c.1254C>T, TT versus CC: OR = 2.30, 95% CI 1.61-3.28; CT versus CC: OR = 1.32, 95% CI 1.05-1.67; TT/CT versus CC: OR = 1.50, 95% CI 1.20-1.86; TT versus CT/CC: OR = 2.00, 95% CI 1.43-2.80; T versus C: OR = 1.47, 95% CI 1.25-1.73; for c.1517G>C, CC versus GG: OR = 1.90, 95% CI 1.34-2.69; GC versus GG: OR = 1.56, 95% CI 1.24-1.97; CC/GC versus GG: OR = 1.63, 95% CI 1.31-2.03; CC versus GC/GG: OR = 1.52, 95% CI 1.10-2.11; C versus G: OR = 1.45, 95% CI 1.23-1.70). The allele-T of c.1254C>T and allele-C of c.1517G>C genetic variants may contribute to HCC susceptibility in Chinese Han population. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

47. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].

Author

Xu B, Tian F, Yu J, Song Y, Shi J, Zhang B, Zhang Y, Yuan Z, Wu Q, Zhang Q, Nan K, Sun Q, Li W, Hu J, Bi J, Meng C, Dai H, Jiang H, Yue S, Cao B, Sun Y, Wang S, Tong Z, Shen P, Wu G, Tang L, Deng Y, Jia L, Shen K, Zhuang W, Xie X, Wu Y, and Chen L

Subjects
Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols, Carboplatin administration & dosage, Carboplatin adverse effects, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Docetaxel, Epirubicin administration & dosage, Epirubicin adverse effects, Female, Humans, Incidence, Induction Chemotherapy, Neutropenia chemically induced, Neutropenia epidemiology, Polyethylene Glycols, Recombinant Proteins administration & dosage, Taxoids administration & dosage, Taxoids adverse effects, Antineoplastic Agents adverse effects, Breast Neoplasms drug therapy, Carcinoma, Non-Small-Cell Lung drug therapy, Granulocyte Colony-Stimulating Factor therapeutic use, Lung Neoplasms drug therapy, Neutropenia prevention & control
Abstract

Objective: To explore the safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer (NSCLC), and to provide the basis for clinical application., Methods: According to the principle of open-label, randomized, parallel-group controlled clinical trial, all patients were randomized by 1∶1∶1 into three groups to receive PEG-rhG-CSF 100 μg/kg, PEG-rhG-CSF 6 mg, or rhG-CSF 5 μg/kg, respectively. The patients with breast cancer received two chemotherapy cycles, and the NSCLC patients received 1-2 cycles of chemotherapy according to their condition. All patients were treated with the combination chemotherapy of TAC (docetaxel+ epirubicin+ cyclophosphamide) or TA (docetaxel+ epirubicin), or the chemotherapy of docetaxel combined with carboplatin, with a 21 day cycle., Results: The duration of grade 3-4 neutropenia in the PEG-rhG-CSF 100 μg/kg and PEG-rhG-CSF 6 mg groups were similar with that in the rhG-CSF 5 μg/kg group (P>0.05 for all). The incidence rate of grade 3-4 neutropenia in the PEG-rhG-CSF 100 μg/kg group, PEG-rhG-CSF 6 mg group, and G-CSF 5 μg/kg group were 69.7%, 68.4%, and 69.5%, respectively, with a non-significant difference among the three groups (P=0.963). The incidence rate of febrile neutropenia in the PEG-rhG-CSF 100 μg/kg group, PEG-rhG-CSF 6 mg group and G-CSF 5 μg/kg group were 6.1%, 6.4%, and 5.5%, respectively, showing no significant difference among them (P=0.935). The incidence rate of adverse events in the PEG-rhG-CSF 100 μg/kg group, PEG-rhG-CSF 6 mg group and G-CSF 5 μg / kg group were 6.7%, 4.1%, and 5.5%, respectively, showing a non-significant difference among them (P=0.581)., Conclusions: In patients with breast cancer and non-small cell lung cancer (NSCLC) undergoing TAC/TA chemotherapy, a single 100 μg/kg injection or a single fixed 6 mg dose of PEG-rhG-CSF at 48 hours after chemotherapy show definite therapeutic effect with a low incidence of adverse events and mild adverse reactions. Compared with the continuous daily injection of rhG-CSF 5 μg/kg/d, a single 100 μg/kg injection or a single fixed 6 mg dose of PEG-rhG-CSF has similar effect and is more advantageous in preventing chemotherapy-induced neutropenia.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results